A multinational phase II trial of bevacizumab with low-dose interferon-alpha 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN

B. Melichar, S. Bracarda, V. Matveev, B. Alekseev, S. Ivanov, A. Zyryanov, R. Janciauskiene, E. Fernebro, P. Mulders, S. Osborne, S. Jethwa, G. Mickisch, M. Gore, R.J.A. van Moorselaar, M. Staehler, N. Magne, J. Bellmunt

Research output: Contribution to journalArticleAcademicpeer-review

25 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)2396-2402
JournalAnnals of Oncology
Issue number9
Publication statusPublished - 2013

Cite this